NCT02182362已完成1 期
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of 20 mg, 48 mg, 120 mg, and 240 mg Once a Day of BI 201335 NA (Oral Solution) in Healthy Male Subjects, in a Randomized Double Blind, Placebo Controlled Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 主要终点
- Number of patients with abnormal findings in physical examination
研究概览
简要总结
The main objective was to investigate the safety, tolerability and the pharmacokinetics (PK) of BI 201335 NA in healthy male subjects without Gilbert's syndrome or polymorphism (GS) following oral administration of a single dose (Day 1) and repeated doses (Days 4-24) of 20 mg, 48 mg, 120 mg, and 240 mg. Additionally, the safety, tolerability, and the PK of the highest tolerated dose of BI 201335 NA (determined during the multiple-rising-dose phase) were assessed in healthy male subjects with GS over a 28-day continuous drug administration period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Complete medical history, physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead ECG (electrocardiogram), and clinical laboratory tests
- •Age ≥18 and Age ≤55 years
- •BMI ≥18.5 and BMI ≤30 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Subjects with polymorphisms associated with Gilbert's syndrome will be excluded from the initial 4 groups of the multiple rising dose phase of the study. However, only subjects with Gilbert's polymorphism will be allowed to participate in the last group which will be treated with the highest tolerated dose determined in the multiple rising dose phase of the trial
- •Prior history of jaundice for subjects without Gilbert's polymorphism
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 30 days prior to screening until trial completion
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoking (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking during the trial
- •Alcohol abuse (more than 60 g/day)
- •Inability to refrain from alcohol during the trial
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for TdP (Torsades de points) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
研究组 & 干预措施
BI 201335 NA in rising doses
Experimental
single dose of BI 201335 NA on day 1, multiple dosing days 4-24
干预措施: BI 201335 NA (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BI 201335 NA
Experimental
highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
干预措施: BI 201335 NA (Drug)
结局指标
主要结局
Number of patients with abnormal findings in physical examination
时间窗: Baseline and up to 46 days
Number of patients with clinically relevant changes in vital signs (blood pressure (BP), pulse rate (PR))
时间窗: Baseline and up to 32 days
Number of patients with clinically relevant changes in 12-lead ECG (electrocardiogram)
时间窗: Baseline and up to 32 days
Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, urinalysis)
时间窗: Baseline and up to 32 days
Incidence of adverse events
时间窗: up to day 46
Assessment of tolerability by investigator
时间窗: Day 28 or 32
次要结局
- Cmax (maximum measured concentration of the analyte in plasma)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- λz (terminal rate constant in plasma)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- tmax (time from dosing to maximum measured concentration of the analyte in plasma)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- t1/2 (terminal half-life of the analyte in plasma)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- MRTpo (mean residence time of the analyte in the body after single oral administration)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- Vz/F (apparent volume of distribution during the terminal phase λz)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- λz,ss (terminal rate constant in plasma at steady state)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following oral administration)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- CL/F (apparent clearance of the analyte in plasma)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment)
- Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- t1/2,ss (terminal half-life of the analyte in plasma at steady state)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
- CL/F,ss (apparent clearance of the analyte in the plasma at steady state following multiple oral dose administration)(Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose)
研究者
相似试验
已完成
1 期
A Study to Test How Well Men Tolerate Different Doses of BI 3006337HealthyNCT05076422Boehringer Ingelheim80
已完成
1 期
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male SubjectsHealthyNCT02182323Boehringer Ingelheim74
已完成
1 期
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy MenHealthyNCT06232252Boehringer Ingelheim38
已完成
1 期
A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the BodyHealthyNCT05633862Boehringer Ingelheim24
已完成
1 期
This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.HealthyNCT03576144Boehringer Ingelheim50